AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02976389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive: Low
Description: Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
Study NCT03707145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation
Description: The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
Study NCT03707145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation
Description: The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
Study NCT03707145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Support
Description: The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
Study NCT03707145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Support
Description: The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
Study NCT03707145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered
Description: The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
Study NCT03707145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empowered
Description: The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
Study NCT04850339 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ANXV
Description: Intravenous infusion
Study NCT04850339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study NCT01152073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
Study NCT01152073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Second Formulation
Description: Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
Study NCT01152073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Third Formulation
Description: Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
Study NCT03082859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This a randomised cross-over study involving three different modes of exercise which will be compared to a no-exercise control.
Study NCT01195311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB024360
Description: INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
Study NCT02976857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR-011
Description: lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.
Study NCT02957383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wavelength
Description: wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
Study NCT02957383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensity
Description: Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2
Study NCT02792517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: A single dose of erenumab administered in the abdomen.
Study NCT02792517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethynil Estradiol/Norgestimate Oral Contraceptive
Description: Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.
Study NCT02573597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Continuous or bolus administration
Study NCT02573597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Continuous or bolus administration
Study NCT01068860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Description: Single subcutaneous injection of Canakinumab 150 mg.
Study NCT01068860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Canakinumab
Description: Single subcutaneous injection of Placebo to Canakinumab.
Study NCT04636788 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Venous sampling
Description: venous sampling of 12ml
Study NCT03405831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine, oral tablets, 5 mg, coated in gelatine capsules to ensure blinding, 1 capsule twice a day, for a period of 12 weeks
Study NCT03405831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, gelatine capsules to ensure blinding, 1 capsule twice daily, for a period of 12 weeks
Study NCT02105467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazoprevir 100mg / Elbasvir 50 mg FDC
Study NCT02105467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100mg / Elbasvir 50 mg FDC
Study NCT02105467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Grazoprevir / Elbasvir 50 mg FDC
Study NCT04445025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix 200 MG
Description: Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation
Study NCT04445025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate 3.75 MG/ML
Description: Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation
Study NCT04445025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lab work
Description: Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw
Study NCT04445025 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lab work
Description: Serum follicle stimulating hormone (FSH), estradiol, luteinizing hormone (LH), progesterone, human chorionic gonadotropin (hCG), serum for microarray analysis, complete blood count, and chemistry panel with liver functions levels will be drawn via blood draw
Study NCT04314037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesol (Test)
Description: Participant will receive coated cesol tablet in sequence 1 (Day 1 and Day 15) and in sequence 2 (Day 8 and Day 22). A washout period of 7 days will be maintained between 4 treatment periods.
Study NCT04314037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biltricide (Reference)
Description: Participant will receive biltricide tablet in Sequence 1 (Day 8 and Day 22) and in sequence 2 (Day 1 and Day 15). A washout period of 7 days will be maintained between 4 treatment periods.
Study NCT03566030 — intervention group
Intervention type: DRUG
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Administered Tenofovir disoproxil fumarate 300 mg QD
Study NCT03566030 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Alafenamide 25 mg
Description: Administered Tenofovir Alafenamide 25 mg QD
Study NCT02843048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: Participants allocated to the Exercise training plus standard medical care group will undergo an exercise-training program of 11 months duration, 3 sessions/week, and 60 minutes/session, starting one month after the surgery. Each exercise session will be supervised and will include 5 major components: i) warm-up, ii) multidirectional jumps, iii) balance, iv) strength and, v) cool down. This structure is planned to meet two main objectives: i) enhance bone formation and, ii) reduce fall risk by improving muscle strength, cardiorespiratory fitness and balance.
Study NCT02843048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard follow-up medical care following bariatric surgery
Study NCT02566772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS3681
Description: TAS3681 will be provided as 100 mg tablets to be administered orally in 28-day cycles. The number of cycles is approximately 6, or until discontinuation criteria is met.
Study NCT00470470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00470470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01296087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6987
Description: TC-6987 50 mg capsule given once daily on Days 1 to 28
Study NCT01296087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule given once daily on Days 1 to 28
Study NCT00218946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 30 % sucrose
Study NCT00218946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacifier
Study NCT00218946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sterile water
Study NCT04337398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks (wearables)
Description: Activity trackers with adaptive weekly step goals, weekly walking groups and coaching.
Study NCT04337398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 weeks (wearables and exergames)
Description: Activity trackers with adaptive weekly step goals, weekly walking groups, coaching and exercise programme based on exergames (aerobic, resistance and stretching training three weekly group sessions).
Study NCT00593515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family cognitive behavioral therapy
Description: 12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
Study NCT03457012 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study NCT02582840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose
Study NCT00593515 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-focused cognitive behavioral therapy
Description: 12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
Study NCT03014154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Study NCT01096862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: oral
Study NCT01096862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01998919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
Study NCT01998919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
Study NCT01998919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: 1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
Study NCT01998919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
Study NCT01998919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
Study NCT01998919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
Study NCT01998919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: 5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
Study NCT01998919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: 5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
Study NCT03866213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BiliSpec
Description: BiliSpec will quantitatively measure the bilirubin content of a neonatal blood sample.
Study NCT04537884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX1325
Description: Investigational drug intravitreal injection
Study NCT03839628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Physical Activity
Description: Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
Study NCT01302743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Metformin
Description: Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
Study NCT01302743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 2: Cinnamon Bark
Description: Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days
Study NCT01302743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 3: Cinnulin PF
Description: Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
Study NCT03525704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline Solution Enriched
Description: Sterile single dose, Preservative Free, PH Balanced, Enriched with IONs rinsing and Insertion Solution
Study NCT03525704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline Rinse Solution
Description: sterile unit dose non-preserved, 0.9% NaCl (normal saline) solution i
Study NCT00665405 — intervention group
Intervention type: RADIATION
Intervention: CT scan
Description: Thoracic CT scan
Study NCT02547012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole+amox+levo+tetra
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
Study NCT00491322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol 50000 international units once a week for 12 weeks
Study NCT02547012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole+amox+levo
Description: esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
Study NCT01444339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 1
Description: 0.5 mL, intramuscular (1 middle dose)
Study NCT01444339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 2
Description: 0.5 mL, intramuscular (2 low doses)
Study NCT01444339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 3
Description: 0.5 mL, intramuscular (2 middle doses)
Study NCT01444339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 4
Description: 0.5 mL, intramuscular (2 middle doses)
Study NCT01444339 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine Formulation 5
Description: 0.5 mL, intramuscular (2 high doses)
Study NCT01444339 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL, intramuscular
Study NCT03644342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirapaib
Description: (see treatment regimen and method of treatment assignment)
Study NCT03711097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanish XT Dental Varnish
Description: Varnish will be applied to the front surface of the intervention upper central and lateral incisors
Study NCT03099031 — intervention group
Intervention type: DRUG
Intervention: Tinzaparin
Description: Subcutaneous injection of 175 IU/kg once daily for 6 months
Study NCT04670328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: not required
Description: Diagnostic tests( hematological parameters) were assessed.
Study NCT03360383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous vertebroplasty
Description: Undertake Percutaneous vertebroplasty with polymethylmetacrylate bone cement.
Study NCT03360383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: complete on bed with prevention of complications
Study NCT00491322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ergocalciferol placebo
Description: Ergocalciferol placebo once a week for 12 weeks
Study NCT00648583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Tablets 24 mg
Description: 24mg, single dose fed
Study NCT00648583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran® Tablets 24 mg
Description: 24mg, single dose fed
Study NCT02277548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica 300 mg
Description: Lyrica 300 mg per day
Study NCT02277548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02513095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium for injectable suspension
Description: Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
Study NCT04530422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir plus Ledipasvir
Description: Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.
Study NCT04530422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus Ledipasvir
Description: Sofosbuvir plus Ledipasvir, once daily for 15 to 21days~* Oseltamivir 150 mg q 12 hours for 10 days ;~* HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for 9 days ; and~* Azithromycin 500mg once daily for 1 day , followed by 250mg once daily for 6 days.
Study NCT04762316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-UF
Description: Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy.
Study NCT04762316 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SB-UF Placebo
Description: Dosage:~-Take 1tablet/2 times/day/in throughout pregnancy.
Study NCT02705664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl Nail Lacquer
Description: Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
Study NCT02705664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urea Ointment
Description: Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
Study NCT02705664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifonazole Cream
Description: Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
Study NCT04483570 — intervention group
Intervention type: PROCEDURE
Intervention: Redo-tethering operation
Study NCT04517630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic
Description: Determine the evolution of NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic at basal, and the 3 , 5 and 7 days after recruitment